



TREATMENT GUIDED BY MOLECULAR FINDINGS IN EARLY-STAGE CANCERS MAKES A DIFFERENCE



J Thorac Oncol. 2021
DOI: <https://doi.org/10.1016/j.jtho.2021.01.1628>
V.Aredo et al
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Significant progression-free survival benefit by targeting EGFR after CRT in stage III EGFR mutated NSCLC



Cancer Discov
2020 Dec;10(12):1826-1841. doi: 10.1158/2159-8290.CD-20-0282. Epub 2020 Oct 18.
Binkley et al
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition

KEAP1 mutations are predictive of very poor local control and OVERALL SURVIVAL when treated with a radiation modality

KEAP1 mutations do not impact local control impact in patients treated with surgery

Clin Transl Radiat Oncol. 2017 Dec; 7: 91-93.
Published online 2017 Nov 4. doi: 10.1016/j.ctro.2017.11.002
Lockney et al
PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT)

SBRT in NSCLC with KRAS mutations is predictive of very poor local control and survival

SBRT in NSCLC with PIK3CA mutations has very poor local control





Fig. 1. Kaplan-Meier curve for local control following lung SBRT for primary or metastatic tumors to lung based on PIK3CA mutation status (p < .001).

PRE-SURGICAL ctDNA IS VERY PROGNOSTIC IN EARLY-STAGE LUNG CANCERS

Nature March 2020
<https://doi.org/10.1038/s41586-020-2140-0>
Received: 30 July 2019
Integrating genomic features for non-invasive early lung cancer detection

